上市企业：石药集团（01093.HK）、东阳光药（06887.HK）、华海药业（600521）、海特生物 （300683）、梓橦宫（832566） 相关企业：珠海同源药业有限公司、重庆圣华曦药业股份有限公司、中山万汉制药有限公司、植恩生物 技术股份有限公司、郑州致和药业有限公司、浙江普洛康裕制药有限公司、浙江普利药业有限公司、浙 江尖峰药业有限公司、浙江华润三九众益制药有限公司、宜昌东阳光长江药业股份有限公司、杨凌科森 生物制药有限责任公司、扬子江药业集团有限公司、武汉人福利康药业有限公司、天津汉瑞药业有限公 司、天方药业有限公司、天地恒一制药股份有限公司、遂成药业股份有限公司、苏州二叶制药有限公 司、四川子仁制药有限公司、四川依科制药有限公司 内容概要：我国抗流感药物市场需求受流感发病人数影响较大，2023年我国流感疫情的影响相对 COVID-19疫情前波及范围更广、持续时间更长，庞大的流感发病人群带动我国抗流感药物市场快速扩 张，据统计，2023年我国抗流感药物行业市场规模达110亿元，同比增长150.00%，2024年，随着我国 流感发病人数的减少，抗流感药物需求也明显缩减，据统计，2024年我国抗流感 ...

Core Viewpoint - The market for antiviral drugs, particularly oseltamivir, is undergoing significant changes due to price adjustments, increased competition from generics, and the emergence of new drugs, leading to a potential reshaping of the industry landscape [1][3][12]. Price Adjustments and Market Dynamics - Zhejiang Province's medical insurance bureau has announced price adjustments for oseltamivir capsules, affecting several manufacturers, including East Sunshine Pharmaceutical [1][4]. - Prior to the collective procurement, oseltamivir capsules were priced over 100 yuan, but the minimum winning price in the seventh national procurement was less than 1 yuan per capsule, representing a 92% reduction from the highest bid [1][5]. - The domestic flu drug market exceeded 10 billion yuan in 2023, with oseltamivir holding over 80% market share, but this is threatened by the rapid growth of Roche's baloxavir marboxil, which saw sales increase from 70 million yuan in 2022 to 630 million yuan in 2023 [2][5]. Competitive Landscape - East Sunshine Pharmaceutical's market share for oseltamivir has dropped to 54.8% as of 2024, facing competition from over 70 other pharmaceutical companies producing generic versions [2][6]. - The company’s sales from oseltamivir products accounted for 81.2%, 86.9%, and 64.2% of total revenue from 2022 to 2024, indicating a significant reliance on this product line [7]. - The expiration of key patents for oseltamivir will intensify competition, with the last synthesis process patent expiring in March 2024 [5][6]. New Drug Developments - The introduction of new antiviral drugs, such as baloxavir marboxil and PB2-targeting drug, has the potential to disrupt the existing market, particularly with baloxavir's pediatric formulation targeting children aged 5 to 12 [8][10]. - The increasing resistance rates of flu viruses to existing treatments, including oseltamivir, highlight the urgent need for new drug development [10][11]. - The approval of multiple new antiviral drugs in China and the U.S. indicates a growing focus on innovative treatments to address flu virus mutations and resistance issues [9][10]. Future Outlook - The ongoing shifts in the antiviral drug market, driven by pricing pressures, patent expirations, and the introduction of new therapies, suggest that companies like East Sunshine Pharmaceutical may need to diversify their product offerings to sustain growth [7][12]. - The competitive landscape is expected to evolve rapidly, with both domestic and international players vying for market share in the antiviral segment [12].

Core Viewpoint - The approval of ZHONGSHENG Pharmaceutical's Angladiwe Tablets by the National Medical Products Administration marks a significant advancement in the treatment of influenza, being the first RNA polymerase PB2 protein inhibitor globally [1] Company Summary - ZHONGSHENG Pharmaceutical (002317) announced the approval of Angladiwe Tablets on May 22, 2025, for the treatment of adult uncomplicated influenza A patients [1] - Angladiwe Tablets are the only antiviral drug in China that has undergone head-to-head Phase III clinical trials against Oseltamivir and received market approval [1] Clinical Trial Results - Phase III clinical trial results indicated that Angladiwe Tablets significantly outperformed the placebo group in seven primary endpoints related to the relief of influenza symptoms, achieving statistical significance [1] - The Angladiwe group demonstrated a nearly 10% reduction in median time to alleviation of total symptoms (TTAS) and fever relief compared to the Oseltamivir group [1]